SAN DIEGO--(BUSINESS WIRE)--Suven Life Sciences Ltd, a Drug Discovery and development company announced today at Bio-2008, San Diego that they commenced Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia.
